Clinical trial · Interventional
Effect of NUTRICAN to Improve Nutritional Status in Cancer Patients
The Effect of Oral Nutrition Supplement Formulas (ONS) and Diet Counseling on Improvement of Nutritional Status, Knowledge, Attitudes, and Behavior of Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to evaluate the efficacy oral nutrition supplement (ONS) in malnutrition/high risk malnutrition cancer patients. The main questions it aims to answer: 1. Are there differences in knowledge, attitude and behaviour scores in cancer patients who receive cancer-specific ONS compared to those who do not receive cancer-specific ONS? 2. Is there a difference in nutritional status as assessed by average body weight, body mass index (BMI), haemoglobin (Hb), and albumin levels in cancer patients who receive cancer-specific ONS compared to those who do not receive cancer-specific ONS?
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Cervix | — | UNRESOLVED | — |
| Cancer, Lung | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Malnutrition; Protein | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| NUTRICAN | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- ONS (oral nutrition supplement) group
- description
- ONS will be consumed 3 times a day, for 8 weeks. Per serving/sachet ONS (±81g) contains 350 kcal of energy, 9 g of fat, 20 g of protein, 48 g of carbohydrates, 400 mg of DHA (Docosahexaenoic acid), 300 mg of EPA (Eicosapentaenoic Acid) 0.92 g of Omega-3, 1 g of L-Valine, 2.1 g of L-. Isoleucine 1.1 g, L-Leucine 2.1 g, Sodium 75 mg, 12 vitamins and 9 minerals. Consumed as a morning snack (between breakfast and lunch); afternoon snack (between lunch and dinner) and evening snack (before bedtime). Subject will also received dietary counseling for 8 weeks
- interventionNames
- Dietary Supplement: NUTRICAN
- type
- NO_INTERVENTION
- label
- Control group
- description
- only received dietary counseling for 8 weeks without ONS supplementation.
Primary outcomes (7)
- measure
- Nutrition consumption knowledge score
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed lung and ob-gyn cancer patients (who have not undergone therapy or are currently undergoing therapy) * Aged greater than or equal to 18 years * Patients with a performance status score of 0 - 2 * Have inadequate food intake \>5 days or: 1. BMI/body mass index \<18.5 kg/m2 or 2. There is a \>10% weight loss in the last 3-6 months or 3. BMI \<20 kg/m2 or 4. There is \>5% weight loss in the last 3-6 months with * Intervention group subjects are willing to take ONS orally for 8 weeks * Intervention group subjects, if they have taken other brands of ONS, are willing to stop taking ONS 2 weeks prior to the study. Exclusion Criteria: * Pregnant and breastfeeding, except for female subjects with one of the following criteria: 1. Have a history of hysterectomy (surgical removal of the uterus) and/or bilateral oophorectomy (surgical removal of the ovaries). 2. Medically confirmed ovarian failure (decreased ovarian function) 3. Achieved post menopausal status, defined as: cessation of regular menstruation for at least 12 consecutive months in the absence of pathological or physiological causes. * Renal insufficiency (eGFR ( Estimated Glomerular Filtration Rate ) \<15 mL/min/1.73 m2 or significant increase in urea/creatinine or having to be on a low protein diet) * Liver insufficiency (SGOT (Serum Glutamic Oxaloacetic Transaminase) /SGPT (Serum Glutamic Pyruvic Transaminase) values ≥3 times the normal limit)
References
Publications (0)
Data not yet available